Lei Fengyang, Haque Mohammad, Sandhu Praneet, Ravi Swetha, Song Jianyong, Ni Bing, Zheng Songguo, Fang Deyu, Jia Hongyan, Yang Jin-Ming, Song Jianxun
Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, PA, USA.
Institutes of Irradiation/Immunology, The Third Military Medical University, Chongqing, China.
Oncoimmunology. 2017 May 30;6(7):e1334027. doi: 10.1080/2162402X.2017.1334027. eCollection 2017.
Optimal approaches to differentiate tumor antigen-specific cytotoxic T lymphocytes (CTLs) from pluripotent stem cells (PSCs) remain elusive. In the current study, we showed that combination of priming through Notch ligands and development facilitated the generation of tumor Ag-specific CTLs that effectively inhibited tumor growth. We co-cultured the murine induced PSCs (iPSCs) genetically modified with tyrosinase-related protein 2 (TRP2)-specific T cell receptors with OP9 cell line expressing both Notch ligands Delta-like 1 and 4 (OP9-DL1/DL4) for a week before adoptively transferred into recipient C67BL/6 mice. Three weeks later, B16 melanoma cells were inoculated subcutaneously, and the antitumor activity of the iPSC-derived T cells was assessed. We observed the development of the TRP2-specific iPSC-CD8 T cells that responded to Ag stimulation and infiltrated into melanoma tissues, significantly inhibited the tumor growth, and improved the survival of the tumor-bearing mice. Thus, this approach may provide a novel effective strategy to treatment of malignant tumors.
区分肿瘤抗原特异性细胞毒性T淋巴细胞(CTL)与多能干细胞(PSC)的最佳方法仍不清楚。在当前研究中,我们表明通过Notch配体启动和发育的组合促进了肿瘤抗原特异性CTL的产生,这些CTL有效抑制了肿瘤生长。我们将用酪氨酸酶相关蛋白2(TRP2)特异性T细胞受体进行基因改造的小鼠诱导PSC(iPSC)与表达Notch配体Delta样1和4的OP9细胞系(OP9-DL1/DL4)共培养一周,然后将其过继转移到受体C57BL/6小鼠体内。三周后,皮下接种B16黑色素瘤细胞,并评估iPSC衍生T细胞的抗肿瘤活性。我们观察到TRP2特异性iPSC-CD8 T细胞的发育,这些细胞对抗原刺激有反应并浸润到黑色素瘤组织中,显著抑制了肿瘤生长,并提高了荷瘤小鼠的存活率。因此,这种方法可能为恶性肿瘤的治疗提供一种新的有效策略。